Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioRestorative TherapiesFRA:9OF +1.61%59 3-Year EBITDA Growth Rate is 30.80% as of Mar. 2026, which is 48% below its 10-year median of 59.75. GuruFocus rates FRA:9OF with a GF Score™ of 59/100 and a GF Value™ of €1.28 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,131 Biotechnology companies, BioRestorative Therapies ranks better than 68.88% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 30.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 41.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 64.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioRestorative Therapies was 85.10% per year. The lowest was 24.80% per year. And the median was 59.75% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
BioRestorative Therapies 3-Year EBITDA Growth Rate Related Terms
FRA:9OF vs LIMN, BOLT, TRAW: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, BioRestorative Therapies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 30.80% mean?
BioRestorative Therapies (FRA:9OF) has a 3-Year EBITDA Growth Rate of 30.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioRestorative Therapies and its competitors. This is 48% below median its historical median of 59.75. Over the past decade, BioRestorative Therapies' 3-Year EBITDA Growth Rate has ranged from 24.80 to 85.10. According to the industry distribution chart, BioRestorative Therapies ranks #352 out of 1131 companies in the Biotechnology industry, placing it in the top 31.1%.
Is BioRestorative Therapies' 3-Year EBITDA Growth Rate too high?
BioRestorative Therapies' current 3-Year EBITDA Growth Rate of 30.80% is 48% below median its 10-year median of 59.75. Over the past 10 years, this metric has ranged from a low of 24.80 to a high of 85.10. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. BioRestorative Therapies' value of 30.80% is 106.7% above this industry median. Based on the distribution chart, BioRestorative Therapies ranks #352 out of 1131 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioRestorative Therapies has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' 3-Year EBITDA Growth Rate compare to LIMN and BOLT?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #352 out of 1131 companies for 3-Year EBITDA Growth Rate. This puts BioRestorative Therapies in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. BioRestorative Therapies' value of 30.80% is 106.7% above this benchmark. Historically, BioRestorative Therapies' own 3-Year EBITDA Growth Rate has ranged from 24.80 to 85.10 over the past decade. While the company's 10-year median is 59.75 vs. the industry median of 14.90, BioRestorative Therapies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRestorative Therapies's current 3-Year EBITDA Growth Rate of 30.80% is 106.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioRestorative Therapies and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current 3-Year EBITDA Growth Rate is 30.80%, which is 48% below median its own 10-year median of 59.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.28, compared to a current price of €0.19 — trading 85.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 30.80%, which is 48% below median its 10-year median of 59.75 and 106.7% above the Biotechnology industry median of 14.90. BioRestorative Therapies' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current 3-Year EBITDA Growth Rate is 30.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.19 is trading 85.2% below its estimated GF Value™ of €1.28.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for FRA:9OF:
3-Year EBITDA Growth Rate: 30.80% (48% below median its 10-year median of 59.75)
GF Value™: €1.28 vs. price of €0.19 (85.2% below fair value)
Industry Position: 106.7% above the Biotechnology median (#352 of 1131)
No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
59GF Score
Get the complete analysis for FRA:9OF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9OF has been successfully added to your 
